What it's for (Indications)
- Everolimus, often known by its brand name Certican in transplant settings, is primarily indicated for the prophylaxis of organ rejection in adult kidney and heart transplant recipients.
- For kidney transplantation, it is used in combination with reduced-dose ciclosporin and corticosteroids, typically initiated a few weeks post-transplant.
- In heart transplantation, it is generally administered in conjunction with standard doses of ciclosporin and corticosteroids.
- Another formulation of everolimus (e.
- g.
- , Afinitor) is also widely used in various oncological indications, including advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic, gastrointestinal, or lung origin, advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women, and subependymal giant cell astrocytoma (SEGA) and TSC-associated seizures in patients with tuberous sclerosis complex (TSC).
- It is crucial for healthcare professionals to differentiate between the specific indications and corresponding dosage regimens for different everolimus formulations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of everolimus (Certican) is highly individualized and meticulously adjusted based on the specific organ transplant, patient's immunological risk, co-administered immunosuppressants, and therapeutic drug monitoring (TDM) to achieve optimal blood trough concentrations. For adult kidney transplant prophylaxis, an initial dose of 0.75 mg orally twice daily is commonly used, aiming for target trough levels of 3-8 ng/mL when used with reduced-dose ciclosporin. In adult heart transplant patients, a typical initial dose is 1.5 mg orally twice daily, targeting similar trough concentrations. Dosage adjustments are frequently necessary, particularly in the presence of hepatic impairment, significant drug-drug interactions (e.g., with strong CYP3A4 inhibitors or inducers), or changes in concomitant immunosuppressive therapy. Close monitoring of everolimus blood levels is paramount to ensure efficacy, minimize toxicity, and prevent organ rejection while managing side effects. Doses for oncological indications differ significantly, often involving higher daily doses (e.g., 10 mg once daily) without the same TDM requirements as in transplantation. |
Safety & Warnings
Common Side Effects
- Everolimus therapy can be associated with a broad spectrum of adverse effects, reflecting its systemic immunosuppressive and antiproliferative properties.
- Common side effects include peripheral edema, hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), hypertension, anemia, thrombocytopenia, leukopenia, and proteinuria.
- Gastrointestinal disturbances such as stomatitis (mouth ulcers), diarrhea, and nausea are also frequently reported.
- A significant and potentially life-threatening pulmonary complication is non-infectious pneumonitis, which can manifest as cough, dyspnea, or fever.
- Other notable adverse events include new-onset diabetes mellitus, increased susceptibility to infections (bacterial, viral, fungal, protozoal) due to immunosuppression, and an elevated risk of malignancies, particularly lymphomas and skin cancers.
- Impaired wound healing is a known issue, especially in the perioperative period, and renal function impairment, especially when everolimus is combined with calcineurin inhibitors, requires vigilant monitoring.
Serious Warnings
- Black Box Warning: Everolimus (Certican), like other immunosuppressive agents, carries several critical warnings that necessitate rigorous medical oversight and patient counseling, equivalent to a 'Black Box Warning' in their clinical significance. **1. Increased Susceptibility to Infection:** Patients receiving everolimus are at significantly increased risk for developing serious and potentially fatal infections, including opportunistic infections (bacterial, fungal, viral, protozoal). These can include BK virus nephropathy, cytomegalovirus (CMV) disease, polyomavirus-associated nephropathy (PVAN), and other severe infections leading to hospitalization or death. Close monitoring for signs and symptoms of infection and prompt treatment are essential to mitigate these risks. **2. Increased Risk of Malignancy:** Immunosuppressive therapy, including everolimus, increases the risk of developing lymphomas and other malignancies, particularly skin cancers. The overall risk is generally considered to be related to the intensity and duration of immunosuppression rather than to the specific agent. Therefore, patients should be regularly monitored for the appearance of new or worsening malignancies, and protective measures against sun exposure should be advised to reduce the risk of skin cancer. **3. Decreased Renal Function:** Concomitant use of everolimus with calcineurin inhibitors (CNIs) such as ciclosporin may lead to decreased renal function. This risk underscores the importance of careful and routine monitoring of renal function parameters (e.g., serum creatinine, glomerular filtration rate). Dose adjustments of both everolimus and the CNI may be required to maintain acceptable renal function and prevent long-term graft damage.
- Patients receiving everolimus require rigorous and continuous monitoring due to the potential for severe and life-threatening adverse events.
- Immunosuppression can lead to a heightened risk of developing serious infections, including opportunistic infections (e.
- g.
- , BK virus nephropathy, cytomegalovirus [CMV] disease, polyomavirus-associated nephropathy, and severe fungal infections), which may result in graft loss or death.
- Regular surveillance for signs and symptoms of infection is therefore crucial.
- The risk of developing new-onset malignancies, particularly lymphomas and skin cancers, is also increased in immunosuppressed patients receiving everolimus; hence, routine cancer screening is recommended.
- Non-infectious pneumonitis is a critical pulmonary toxicity that mandates prompt investigation of any new or worsening respiratory symptoms; dose reduction or discontinuation may be necessary.
- Hyperglycemia, hyperlipidemia, and hypertension are common metabolic complications that should be managed aggressively.
- Impaired wound healing is a known complication, particularly in the immediate post-transplant period, and angioedema has been reported when everolimus is used concurrently with ACE inhibitors.
How it Works (Mechanism of Action)
Everolimus is a potent and orally active immunosuppressant that functions as a specific inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase that plays a pivotal role in regulating cell growth, proliferation, angiogenesis, and metabolism. It achieves its immunosuppressive effect by binding to the intracellular protein FKBP-12, forming a complex that then directly inhibits the activity of mTOR Complex 1 (mTORC1). This inhibition blocks downstream signaling pathways, including those involved in protein synthesis (e.g., S6 kinase, 4E-BP1), ultimately leading to G1 cell-cycle arrest and a reduction in cell proliferation. In the context of organ transplantation, this mechanism effectively inhibits activated T-lymphocyte proliferation and B-cell activation in response to cytokine stimulation, thereby suppressing the adaptive immune response and preventing allograft rejection. In oncology, its anti-proliferative and anti-angiogenic effects contribute to tumor growth inhibition by limiting cellular resources required for rapid expansion.
Commercial Brands (Alternatives)
No other brands found for this formula.